Literature DB >> 21530682

Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice.

Xiao-Hui Huyan1, Ying-Ping Lin, Tao Gao, Rong-Yi Chen, Yi-Ming Fan.   

Abstract

There has been lack of the uniform standard for establishment of animal immunodepressive models induced by cyclophosphamide (CTX), and the information about the immunosuppressive effect of CTX on peripheral blood lymphocyte subsets in rodents. Here we describe a CTX-induced mouse model and try to establish a feasible immunosuppressive model for studying the fungal pathogenicity. Balb/c mice received two intraperitoneal injections of different CTX doses (50-200 mg/kg) at 2-day intervals. Peripheral whole blood collected at different time-points before and after CTX injection was used to detect white blood cells (WBCs), lymphocytes and their subsets by automated hematology analyzer and flow cytometry, respectively. WBCs and lymphocytes in all groups except CTX50 (50 mg/kg CTX) group commenced to decrease in a dose-dependent manner on day 1, reached the nadir on day 4, rebounded on day 10, and declined again on day 17 after CTX treatment. Low dose (50 mg/kg) CTX produced no obvious change of percentage of CD3(+), CD4(+) and CD8(+) T cells and CD19(+) cells, but high doses (100 or 150 mg/kg) yielded a significant decrease of CD3(+) and CD4(+) cells on day 4 and CD19(+) cells on day 10, and increase of CD8(+) cells on day 4. The CD4(+)/CD8(+) ratio decreased on day 4, followed by a rebound thereafter when treated with 3 different doses of CTX. The results indicate that two intraperitoneal injections of CTX at 150 mg/kg at 2-day intervals may establish good immunosuppressive models of Balb/c mice for studying the fungal pathogenicity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530682     DOI: 10.1016/j.intimp.2011.04.011

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  37 in total

1.  Experimental pathogenicity of a clinical isolate of Trichosporon dermatis in a murine model.

Authors:  Ying-Ping Lin; Yan-Ping Yang; Wen-Ming Huang; Yong-Hua Chen; Shun-Fan Li; Yi-Ming Fan
Journal:  Mycopathologia       Date:  2011-07-13       Impact factor: 2.574

2.  IL-1 Receptor-Knockout Mice Develop Epidermal Cysts and Show an Altered Innate Immune Response after Exposure to UVB Radiation.

Authors:  Nikhil N Kulkarni; Christopher A Adase; Ling-Juan Zhang; Andrew W Borkowski; Fengwu Li; James A Sanford; Daniel J Coleman; Carlos Aguilera; Arup K Indra; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2017-07-25       Impact factor: 8.551

3.  Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population.

Authors:  Sarah Sze Wah Wong; Orhan Rasid; Paris Laskaris; Arnaud Fekkar; Jean-Marc Cavaillon; William J Steinbach; Oumaima Ibrahim-Granet
Journal:  Virulence       Date:  2017-07-06       Impact factor: 5.882

4.  Effects of Nesting Material on the Toxicologic Assessment of Cyclophosphamide in Crl:CD1(ICR) Mice.

Authors:  Catherine P Brochu; Christina L Winnicker; Anne L Provencher; Elaine Debien; Sebastien Gariépy; Brianna N Gaskill
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-07-05       Impact factor: 1.232

5.  The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice.

Authors:  YanHe Lue; Ronald Swerdloff; Junxiang Wan; Jialin Xiao; Samuel French; Vince Atienza; Victor Canela; Kevin W Bruhn; Brian Stone; Yue Jia; Pinchas Cohen; Christina Wang
Journal:  Endocrinology       Date:  2015-09-18       Impact factor: 4.736

6.  A Multimodal Imaging Approach Enables In Vivo Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis.

Authors:  Greetje Vande Velde; Katrien Lagrou; Jennifer Poelmans; Uwe Himmelreich; Liesbeth Vanherp; Luca Zhai; Amy Hillen; Bryan Holvoet; Sarah Belderbos; Matthias Brock; Johan Maertens
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.

Authors:  Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop
Journal:  Cancer Lett       Date:  2018-03-30       Impact factor: 8.679

8.  Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy.

Authors:  Roberto De Pascalis; Lara Mittereder; Nikki J Kennett; Karen L Elkins
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

9.  Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice.

Authors:  Erico S Loreto; Juliana S M Tondolo; Francielli P K de Jesus; Camila M Verdi; Carla Weiblen; Maria I de Azevedo; Glaucia D Kommers; Janio M Santurio; Régis A Zanette; Sydney H Alves
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

10.  A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome.

Authors:  Marianne Delville; Florence Bellier; Juliette Leon; Roman Klifa; Sabrina Lizot; Hélène Vinçon; Steicy Sobrino; Romane Thouenon; Armance Marchal; Alexandrine Garrigue; Juliette Olivré; Soëli Charbonnier; Chantal Lagresle-Peyrou; Mario Amendola; Axel Schambach; David Gross; Baptiste Lamarthée; Christophe Benoist; Julien Zuber; Isabelle André; Marina Cavazzana; Emmanuelle Six
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.